Cover Image

Risk Factors for Liver Disease Cluster Geographically: A Precision Public Health Analysis of a UK City

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	R. Parker, A. Taylor, R. Dukes, B. Wilks, A. Hinkson, D. Burn, I. A. Rowe
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
by: Takao Miwa, et al.
Published: (2026)

The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care
by: Leon A. Adams, et al.
Published: (2026)

Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease
by: Derek D. Satre, et al.
Published: (2024)

Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease
by: Wah Loong Chan, et al.
Published: (2024)

Editorial: Time to Genotype—Genetic Risk and Prognosis in Steatotic Liver Disease
by: Rosellina M. Mancina, et al.
Published: (2025)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
by: Nobuharu Tamaki, et al.
Published: (2025)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Stergios A. Polyzos, et al.
Published: (2024)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
by: Jessica D. Lee, et al.
Published: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
by: Jee‐Fu Huang, et al.
Published: (2026)

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
by: Na Tian, et al.
Published: (2025)

Editorial: Two Common Risks, One Greater Harm—Diabetes and Alcohol in Steatotic Liver Disease
by: Stine Johansen, et al.
Published: (2026)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
by: Kaleb Tesfai, et al.
Published: (2026)

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
by: Glenn Jun Kit Ho, et al.
Published: (2025)

Letter: Post‐HCV Cure, Precision Assessment of Liver Stiffness and Diabetes Risk in Maternal Populations—A Critical Research Need
by: Zihe Guan, et al.
Published: (2025)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
by: Paul Y. Kwo, et al.
Published: (2026)

Letter: Geographic Transportability of Shingles Risk With Advanced IBD Therapies
by: Guofu Mao, et al.
Published: (2026)

Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
by: Donghee Kim, et al.
Published: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
by: Xinglin Li, et al.
Published: (2026)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
by: C. C. Mark Cheah, et al.
Published: (2025)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
by: Pojsakorn Danpanichkul, et al.
Published: (2025)

Editorial: Coeliac Disease and Women's Reproductive Health: A Lifelong Challenge
by: C. Ciacci, et al.
Published: (2025)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria
by: Julie Bonn, et al.
Published: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
by: Xiao‐Dong Zhou, et al.
Published: (2025)

Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis
by: Mushfiqur R. Siddique, et al.
Published: (2025)

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Soroor Owrangi, et al.
Published: (2024)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
by: Ryan Yanzhe Lim, et al.
Published: (2026)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
by: Karen Cheuk‐Ying Ho, et al.
Published: (2025)

Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease
by: Sriram Balasubramani, et al.
Published: (2026)

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
by: Kelly Torosian, et al.
Published: (2025)

Editorial: ICG ‐ R15 by PDD —A Simple Dynamic Tool for Refining Risk Stratification in Compensated Advanced Chronic Liver Disease
by: Yixuan Zhu, et al.
Published: (2025)

Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Population‐Based Cohort Study
by: Yee Hui Yeo, et al.
Published: (2025)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
by: Chunlong Liu, et al.
Published: (2025)

Research Communication: Reflux Disease May Constitute a Risk Factor for Colonic Neoplasia
by: Amnon Sonnenberg, et al.
Published: (2025)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
by: Muhammad Osama, et al.
Published: (2024)

Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death
by: Mathias Jachs, et al.
Published: (2025)

Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
by: Jessica D. Lee, et al.
Published: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Shinya Yokoyama, et al.
Published: (2025)

Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure
by: Amy Sangam, et al.
Published: (2024)

Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy and Addiction Management
by: Raj Vuppalanchi, et al.
Published: (2025)

Steatotic Liver Disease Prevalence in China: A Population‐Based Study and Meta‐Analysis of 17.4 Million Individuals
by: Zhenqiu Liu, et al.
Published: (2025)